US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair

Running, not enrolling · Phase 4

Conditions studied: Aneurysm, Intracranial

In brief

The purpose of this trial is to gather data on the safety and effectiveness of the Contour /Contour 021 System in the treatment of wide-necked bifurcated saccular, intracranial aneurysms for submission to FDA in support of a premarket approval application for the device.

Key facts

Study ID

NCT04852783

Run by

Cerus Endovascular, Inc.

People needed

250

Starts

2021-08-06

Expected to finish

2030-02-01

Last updated by the study team

2026-03-31

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is 18-75 years of age at the time of screening.
• Patient has a single ruptured or unruptured IA requiring treatment. If the patient has an additional IA requiring treatment, the additional IA must not require treatment within 60 days of the index procedure.
• The target IA must have the following characteristics:
• Saccular morphology
• Located at a bifurcation in the anterior or posterior circulation
• Aneurysm neck diameter between 2 and 10 mm and aneurysm equatorial diameter between 2 and 10.5 mm
• Wide-necked, defined as neck size ≥ 4 mm or a dome/neck ratio < 2
• Patient may be treated with Contour without the use of additional implanted devices.
• Patient is able to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule.
• Patient or legally authorized representative has signed and dated an institutional review board (IRB)/Ethics Committee (EC)-approved written informed consent prior to initiation of any study procedures.
• FOR PATIENTS WITH UNRUPTURED ANEURYSM
• Patient meets the criteria outlined in the "Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms" as published by the AHA/ASA FOR PATIENTS WITH RUPTURED ANEURYSM
• Patient meets the criteria outlined in the "Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association" as published by the AHA/ASA.
• Patient must be neurologically stable with Hunt \& Hess Score of I, II or III.

You may not qualify if…

• Anatomy or physiology considered unsuitable for endovascular treatment with the Contour device by the implanting physician and/or the Patient Selection Committee
• Target IA contains other devices/implants (e.g., coils) that could interfere with the correct placement of the Contour device
• Subject has a known, untreatable hypersensitivity to contrast dye, iodine, or any component of the treatment device.
• Contraindication to anticoagulants or anti-platelet medications
• Stenosis of the target IA's parent vessel is >50%
• Anticoagulation medications (e.g., warfarin) that cannot be discontinued
• Acute / chronic renal failure (unless on dialysis) and/or creatinine > 2.00 mg/dl or > 182 μmol/L
• Vascular disease or other vascular anomaly that precluded the necessary access to the aneurysm for use of the study device.
• Clinical, angiographic or CT evidence of vasospasm, vasculitis, an intracranial tumor (except small meningioma) or any other intracranial vascular malformations on presentation.
• Conditions placing them at high risk for ischemic stroke or had exhibited ischemic symptoms such as transient ischemic attacks, minor strokes, or stroke-in-evolution within the prior 60-days.
• Any circulatory, neurovascular, cardiovascular, or neurologic conditions that can result in unstable neurological symptoms (e.g., multiple sclerosis, established seizure disorder).
• modified Rankin Scale (mRS) score ≥ 2 prior to presentation or rupture (as applicable).
• SAH from a non-index aneurysm or any other intracranial hemorrhage within 90 days.
• Physical, neurologic or psychiatric conditions which precluded his/her ability to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule.
• Pregnant, breastfeeding or planning pregnancy in the next 2 years
• Subject is enrolled in another device or drug study in which participation could confound study results.
• Life expectancy of less than 2 years due to an illness or condition other than the index intracranial aneurysm.

Where it is running

• Swedish Medical Center — Englewood, Colorado, United States
• Baptist Health — Jacksonville, Florida, United States
• University of Chicago — Chicago, Illinois, United States
• Advocate Aurora Health — Park Ridge, Illinois, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• UMASS Medical Center — Worcester, Massachusetts, United States
• University at Buffalo Neurosurgery — Buffalo, New York, United States
• NYU Langone Health — New York, New York, United States
• Stony Brook Medicine — Stony Brook, New York, United States
• Montefiore Medical Center — The Bronx, New York, United States
• Westchester Medical Center — Valhalla, New York, United States
• NC Heart and Vascular Research LLC — Raleigh, North Carolina, United States
• The Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• Alejandro Spiotta — Charelston, South Carolina, United States
• Semmes-Murphy Clinic — Memphis, Tennessee, United States
• Medical City Plano — Plano, Texas, United States
• Swedish Neuroscience Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.